Coherus BioSciences (CHRS) Misses Q2 EPS by 8c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.46 -1.35%
EPS Growth %: +23.5%
Financial Fact:
Cost of goods sold: 219.53M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +23.5%
Financial Fact:
Cost of goods sold: 219.53M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.34), $0.08 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $10.25 million versus the consensus estimate of $10.16 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Pacific Booker Minerals Inc. Adopts Advance Notice Policy for Director Elections
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
